Newsroom

Sorted by: Latest

-

Lime Announces Pricing of Initial Public Offering

SAN FRANCISCO--(BUSINESS WIRE)--Neutron Holdings, Inc. (“Lime”), the largest global shared micromobility business, today announced the pricing of its initial public offering of 6,956,522 shares of its common stock, 6,679,791 shares of which are being offered by Lime and 276,731 shares of which are being offered by certain existing stockholders (the “Selling Stockholders”), at an initial public offering price of $25.00 per share. In addition, Lime has granted the underwriters a 30-day option to...
-

Interactive Brokers élargit l'accès à des actions coréennes avec le lancement de Nextrade ATS

GREENWICH, Connecticut--(BUSINESS WIRE)--Interactive Brokers (Nasdaq : IBKR), un courtier mondial automatisé, annonce aujourd'hui le lancement d'actions coréennes via Nextrade, le premier système de trading alternatif (ATS) de la Corée du Sud. L'ajout de Nextrade s'appuie sur le lancement antérieur d'Interactive Brokers de la Korea Exchange (KRX), par l'intermédiaire de laquelle il est devenu le premier grand courtier basé aux États-Unis à fournir aux investisseurs mondiaux un accès direct à de...
-

Interactive Brokers erweitert den Zugang zu koreanischen Aktien durch Einführung des alternativen Handelssystems (ATS) Nextrade

GREENWICH, Connecticut--(BUSINESS WIRE)--Interactive Brokers (Nasdaq: IBKR), ein automatisierter globaler Broker, kündigte heute die Aufnahme des Handels mit ausgewählten koreanischen Aktien über Nextrade an, das erste alternative Handelssystem (Alternative Trading System, ATS) in Südkorea. Die Erweiterung um Nextrade folgt auf die Markteinführung der koreanischen Börse (Korea Exchange, KRX) durch Interactive Brokers, mit der das Unternehmen als erster großer US-amerikanischer Broker globalen A...
-

Shoko Co., Ltd.韩国工厂启动药用辅料“Viscomedi”的商业化生产

东京--(BUSINESS WIRE)--(美国商业资讯)-- 业务涵盖化工、塑料和金属陶瓷三大领域的综合性大宗商品贸易公司Shoko Co., Ltd.(总部:东京都港区;总裁兼首席执行官:Kentaro Watanabe;以下简称“Shoko”)欣然宣布,继2025年6月与Hannong Chemicals Inc.(韩国京畿道安养市;以下简称“Hannong Chemicals”)签署销售框架合作协议后,新型药用辅料“Viscomedi”的制造工厂已顺利竣工,并于2026年2月全面启动商业化生产。 Hannong Chemicals一直致力于开发用于制药领域的“部分中和聚丙烯酸酯”产品,并将其正式命名为“Viscomedi”。该公司持续推进该产品的研发,旨在为制药应用提供一种全新的选择。核心生产设施已于去年11月完工,随后进行了设备调试及各项法规合规工作。 截至2026年6月,Shoko与Hannong Chemicals正基于现有的销售框架协议,就最终协议进行最后阶段的谈判。协议达成后,Shoko计划担任“Viscomedi”的全球独家经销商。 有关本产品的咨询,请访问: ht...
-

Shoko Co., Ltd. Began Commercial Production of Pharmaceutical Excipient “Viscomedi” at Its South Korean Plant

TOKYO--(BUSINESS WIRE)--Shoko Co., Ltd. (Head Office: Minato-ku, Tokyo; President & CEO: Kentaro Watanabe; hereinafter “Shoko”), a comprehensive commodity trading firm engaged in three business domains—chemicals, plastics, and metal & ceramics—is pleased to announce that, following the sales framework agreement announced in June 2025 with Hannong Chemicals Inc. (Anyang, Gyeonggi-do, South Korea; hereinafter “Hannong Chemicals”), the manufacturing plant for the new pharmaceutical excipie...
-

MarinHealth Launches the Haynes Heart & Vascular Institute, Marking a New Era in Cardiovascular Care for the North Bay

GREENBRAE, Calif.--(BUSINESS WIRE)--MarinHealth today announced the official launch of the Haynes Heart & Vascular Institute, recognizing the transformational generosity and enduring legacy of the late Bill Haynes and Reta Haynes, whose vision and philanthropy helped shape one of the North Bay's premier cardiovascular programs. The naming of the Institute celebrates the Haynes family's longstanding commitment to advancing heart care and reflects MarinHealth's continued investment in innovat...
-

Xylem gibt Ernennungen in der Segmentleitung bekannt

WASHINGTON--(BUSINESS WIRE)--Xylem Inc. (NYSE: XYL), ein weltweit führendes Unternehmen für Wasserlösungen, gab heute die Ernennung von zwei Führungskräften zum 1. Juli bekannt, die beide President und Chief Executive Officer Matthew Pine unterstehen. Meredith Emmerich wurde in das Amt des EVP und President, Measurement und Control Solutions, berufen. Zuletzt war sie als EVP und President, Applied Water, bei Xylem tätig. Emmerich wechselte 2024 zu Xylem von der Carrier Global Corporation (NYSE:...
-

UL Solutions Warns of Unauthorized UL Marks on Water-Based Fire Extinguishers

NORTHBROOK, Ill.--(BUSINESS WIRE)--UL Solutions (NYSE: ULS), a global leader in applied safety science, issued a public notice regarding Zinshine Water Based Fire Extinguishers, which bear unauthorized UL Certification Marks for the United States and Canada and may pose safety risks. The affected products have not been evaluated by UL Solutions against the appropriate safety standards, and it is unknown whether they meet any safety requirements. UL Solutions recommends that these fire extinguis...
-

Align Technology Statement on European Commission Proceeding

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today responded to the European Commission’s June 30 press release announcing an investigation involving the Company based on a complaint made by an Align competitor. Align Technology is comm...
-

BeOne Medicines公布BRUKINSA用於一線套細胞淋巴瘤治療的第三期臨床試驗正面結果

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤公司BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)今日公布了第三期MANGROVE研究(BGB-3111-306; NCT04002297)的正面初步主要結果。該研究評估了基礎性BTK抑制劑BRUKINSA® (zanubrutinib)聯合rituximab對比bendamustine聯合rituximab (BR)在既往未經治療的套細胞淋巴瘤(MCL)成人病患中的療效。MANGROVE是第一個在此類病患中評估以BTK抑制劑為基礎的無化療方案對比標準化療免疫療法的第三期全球性隨機試驗。這項關鍵的第三期試驗建立在BRUKINSA治療MCL的已有臨床證據基礎之上。 BeOne Medicines血液學醫學長Amit Agarwal, M.D.博士表示: 「對於新診斷的MCL病患,化療目前是默認選擇。MANGROVE首次證明,BRUKINSA聯合rituximab這一無化療方案,能夠帶來前所未見的無惡化存活期改善,可望在全球重新定義治療...